Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer
Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
Breast Neoplasms
DRUG: bivatuzumab mertansine
Maximum tolerated dose (MTD) of bivatuzumab mertansine, up to day 21
Incidence of adverse events, up to day 21|Number of patients with clinically significant findings in laboratory tests, up to day 21|Number of patients with clinically significant findings in vital signs, up to day 21|Tumor response rate, assessed by response evaluation criteria in solid tumours (RECIST), up to 1 year|Concentration of bivatuzumab mertansine, up to day 21|Concentration of CD44v6 recognising IgG antibodies (anti-CD44v6-IgG), up to day 21|Number of patients with development of human anti-human antibodies (HAHA), up to day 21
Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine